Literature DB >> 23515930

Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period.

Stela Zivčić-Ćosić1, Jasna Lisjak, Sanjin Rački, Zlatko Trobonjača.   

Abstract

PURPOSE: There is a need for methods that would enable monitoring of the effects of immunosuppression on the recipient's immune system to avoid rejection, immunodeficiency-related complications and non-immune toxicities of the drugs used in therapy.
METHODS: This prospective trial included thirty patients who underwent renal transplantation in our center. All patients received an interleukin-2 receptor (IL-2R) antagonist in combination with mycophenolate, corticosteroid and calcineurin inhibitor. During the first 6 weeks after transplantation, the anti-CD3-stimulated proliferative response of peripheral blood T lymphocytes (PBTL) was studied by cell cycle analysis. The proportion of PBTL in different phases of the cell cycle and expression of IL-2R were determined by flow cytometry.
RESULTS: As an effect of quadruple immunosuppressive therapy including IL-2R antagonists, cell cycle analysis showed an incremental decrease in the proliferative response of PBTL during the first 6 weeks after renal transplantation. A sudden drop in the proportion of IL-2R-positive cells was observed immediately after the first dose of the IL-2R antagonist and a significant antiproliferative effect on PBTL after the second dose. In vitro, IL-2R antagonists showed a dose-dependent inhibition of the anti-CD3-stimulated proliferation of PBTL of healthy blood donors.
CONCLUSIONS: Cell cycle analysis of the immune reactivity of renal allograft recipients may represent a valuable tool for the immunological posttransplant follow-up and optimization of the immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23515930     DOI: 10.1007/s11255-013-0413-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  33 in total

Review 1.  The impact of immunosuppressive drugs on the analysis of T cell activation.

Authors:  P Rovira; L Mascarell; P Truffa-Bachi
Journal:  Curr Med Chem       Date:  2000-07       Impact factor: 4.530

2.  Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients.

Authors:  T Haba; K Uchida; A Katayama; Y Tominaga; T Sato; I Watanabe; H Inagaki; T Kimata; K Goto; K Morozumi; A Takeda; S Takahara; K Takahashi; S Oshima
Journal:  Transplant Proc       Date:  2001 Nov-Dec       Impact factor: 1.066

3.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

4.  Adhesion molecule polymorphisms in acute renal allograft rejection.

Authors:  D Khazen; S Jendoubi-Ayed; Y Gorgi; I Sfar; E Abderrahim; T Ben Abdallah; K Ayed
Journal:  Transplant Proc       Date:  2007-10       Impact factor: 1.066

5.  KDIGO clinical practice guideline for the care of kidney transplant recipients.

Authors: 
Journal:  Am J Transplant       Date:  2009-11       Impact factor: 8.086

6.  Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation.

Authors:  J Strehlau; M Pavlakis; M Lipman; M Shapiro; L Vasconcellos; W Harmon; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

7.  Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.

Authors:  Daniel Abramowicz; Yves Vanrenterghem; Jean-Paul Squifflet; Dirk Kuypers; Michel Mourad; Michel Meurisse; Martin Wissing
Journal:  Clin Transplant       Date:  2005-08       Impact factor: 2.863

8.  Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management.

Authors:  Richard Kowalski; Diane Post; Mary C Schneider; Judith Britz; Judy Thomas; Mark Deierhoi; Andrew Lobashevsky; Robert Redfield; Eugene Schweitzer; Alonso Heredia; Elise Reardon; Charles Davis; Carol Bentlejewski; John Fung; Ron Shapiro; Adriana Zeevi
Journal:  Clin Transplant       Date:  2003-04       Impact factor: 2.863

9.  Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.

Authors:  J Goebel; E Stevens; K Forrest; T L Roszman
Journal:  Transpl Immunol       Date:  2000-11       Impact factor: 1.708

10.  Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment.

Authors:  Paul Hutchinson; Matthew Jose; Robert C Atkins; Stephen R Holdsworth
Journal:  Transpl Immunol       Date:  2004 Jun-Jul       Impact factor: 1.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.